Rochester, NY (PRWEB) August 03, 2012
iCardiac Technologies, a leading global provider of cardiac safety assessment services, announced today key financial results from its most recent fiscal year end. The company reported growth in several important areas, including revenue, profitability, customers and personnel. For the fiscal year ended June 30, 2012, the company reported a 61% increase in year-over-year revenue, and enters fiscal 2013 with the largest backlog and customer pipeline in the company’s history. The company also significantly expanded its customer base and now serves 7 of the world’s 10 largest pharmaceutical companies, as well as numerous medium and small biotech, pharmaceutical and medical device clients.
Several customers have used iCardiac’s rigorously generated data in successful drug approvals in the US and Europe.
Additionally, as a result of the company’s strong financial position, iCardiac has completed the redemption of a portion of its Series A shares generating a positive return for the early investors.
“iCardiac’s focus on combining superior science, global capabilities and unparalleled customer service has propelled our continued growth over the past year,” said Mikael Totterman, chief executive officer of iCardiac. “More customers than ever are turning to iCardiac for their critical cardiac safety needs and we are well poised for another record year ahead.”
iCardiac Technologies is a global cardiac safety company that has commercialized advanced research originating at leading academic institutions and pharmaceutical companies. Its reach is international, working with pharmaceutical and medical device clients all over the world to bring the best results to cardiac safety. For more information visit: http://www.icardiac.com/.